| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0091270005281234 |
| P698 | PubMed publication ID | 16291712 |
| P2093 | author name string | James A Dowell | |
| Jennifer Schranz | |||
| Alice Baruch | |||
| Grover Foster | |||
| P2860 | cites work | Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia | Q24563657 |
| Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever | Q28216366 | ||
| Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
| Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. | Q30452376 | ||
| Voriconazole | Q35179545 | ||
| Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety | Q35825582 | ||
| Anidulafungin: review of a new echinocandin antifungal agent | Q35917456 | ||
| Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens | Q39652421 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| Potential for interactions between caspofungin and nelfinavir or rifampin | Q40288945 | ||
| Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole | Q41962141 | ||
| The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent | Q42022417 | ||
| Effect of omeprazole on the steady‐state pharmacokinetics of voriconazole | Q42144423 | ||
| Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus | Q42538222 | ||
| Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration | Q42760098 | ||
| Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients | Q43961537 | ||
| In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. | Q44340936 | ||
| The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human | Q44447139 | ||
| Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal | Q44897892 | ||
| Combination antifungal therapy for invasive aspergillosis | Q45096994 | ||
| Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine | Q45221761 | ||
| Voriconazole: A second-generation triazole | Q47865467 | ||
| P433 | issue | 12 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| voriconazole | Q412236 | ||
| P304 | page(s) | 1373-1382 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | Safety and pharmacokinetics of coadministered voriconazole and anidulafungin | |
| P478 | volume | 45 |
| Q42731827 | Anidulafungin and its role in candida infections |
| Q33490772 | Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination |
| Q36822941 | Anidulafungin in the treatment of invasive fungal infections |
| Q37327122 | Anidulafungin in the treatment of patients with invasive candidiasis |
| Q51339243 | Anidulafungin--challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies. |
| Q36774257 | Anidulafungin--state of affairs from a clinical perspective. |
| Q36723788 | Anidulafungin: a new echinocandin for candidal infections |
| Q46600233 | Anidulafungin: a new echinocandin for the treatment of mycosis |
| Q37345790 | Anidulafungin: a novel echinocandin for candida infections |
| Q37827345 | Anidulafungin: an evidence-based review of its use in invasive fungal infections. |
| Q37854724 | Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections? |
| Q37888751 | Anidulafungin: when and how? The clinician's view |
| Q37159568 | Antifungal agents--clinical pharmacokinetics and drug interactions |
| Q37450705 | Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults |
| Q37204192 | Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis |
| Q37190801 | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin |
| Q44619968 | Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus |
| Q24317436 | Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A |
| Q39458862 | Echinocandins in antifungal pharmacotherapy. |
| Q38462784 | Impact of special patient populations on the pharmacokinetics of echinocandins. |
| Q43169846 | In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin |
| Q30238810 | Infection in Organ Transplantation |
| Q34309603 | Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and |
| Q36825717 | Nosocomial fungal infections: epidemiology, diagnosis, and treatment |
| Q37892536 | Pharmacogenomics of the triazole antifungal agent voriconazole |
| Q39020129 | Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis |
| Q34932630 | Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema |
| Q38681635 | Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients |
| Q37785979 | Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections |
| Q37359613 | Pharmacology and antifungal properties of anidulafungin, a new echinocandin |
| Q34058346 | Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q40337647 | Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry |
| Q39084420 | Significant publications on infectious diseases pharmacotherapy in 2015. |
| Q35635928 | Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults |
| Q36969849 | Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation |
| Q36742397 | The echinocandins |
| Q46600214 | The role of anidulafungin therapy in solid organ transplant recipients |
| Q36624970 | The safety of anidulafungin |
| Q35959489 | Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature |
| Q47697132 | Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence |
| Q86999162 | [Liver dysfunctions in intensive care patients--consequences for the treatment of invasive Candida infections] |
| Q45942595 | [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins]. |
| Q45942588 | [Role of anidulafungin in solid organ transplant recipients]. |
Search more.